Pediatric cancer is finally seeing policy progress. Healthcare leaders still have work to do. | Viewpoint

Pediatric cancer has long occupied one of healthcare’s most uncomfortable categories: universally understood as devastating, yet still not supported with the level of investment, infrastructure and urgency the crisis demands. That may finally be starting to change.

Recent federal action in the 2026 spending package, alongside a growing push to use better data infrastructure and artificial intelligence in pediatric cancer research, signals real momentum in a field that has too often been forced to operate on urgency alone.

But hope is not the same as progress.

The harder truth is that pediatric cancer still sits inside a system that underserves it at nearly every level: research, care access, drug development and long-term survivorship. Childhood cancer still receives only a small fraction of overall cancer research funding despite being the leading disease-related cause of death among children in the United States. In 2025, the National Cancer Institute estimated that 9,550 children under age 15 would be diagnosed with cancer and about 1,050 would die from the disease.

That is the tension healthcare leaders should confront now. There is more momentum than there has been in years, but there is also a longer road ahead than recent headlines suggest.

Progress in Washington matters—But it does not erase structural gaps

The latest policy progress matters because it strengthens pieces of the pediatric cancer ecosystem that directly shape outcomes. Over the past decade, bipartisan efforts such as the STAR Act, the RACE for Children Act and the Childhood Cancer Data Initiative have helped advance research, drug development and data-sharing.

Still, despite these bipartisan efforts, the field remains structurally fragile. The AACR’s 2025 Pediatric Cancer Progress Report makes the point clearly: sustained federal investment is essential not just for research, but for clinical trials, data infrastructure and the future workforce. In pediatric oncology, there is very little excess capacity. When funding slows or programs weaken, the damage is immediate and disproportionate.

Pediatric cancer is still a family-led cause

One of the most overlooked truths about pediatric cancer is that this field has advanced as far as it has because families refused to let it be ignored.

From the outside, pediatric cancer research can look purely clinical. In reality, much of its momentum has come from parents, survivors, advocates and nonprofits that stepped in where market incentives and public funding fell short. AACR notes that philanthropic organizations have played an important role in supporting both pediatric cancer research and clinical trials, helping fill gaps that industry has often not addressed.

That should matter to healthcare leaders. When a field depends this heavily on family-driven advocacy and philanthropy to sustain basic progress, that is not proof the system is functioning well. It is evidence that too much of the burden has been pushed outward.

Part of the problem is economic. Investors and drug developers naturally gravitate toward larger patient populations and clearer commercial returns. Childhood cancers, by contrast, are collectively rare, making up only about 1% to 3% of cancers diagnosed annually in the United States. That commercial logic has real clinical consequences: many pediatric cancer drugs are still adapted from adult oncology regimens, and some childhood cancers have very few dedicated therapeutic pipelines as a result.

When treatments are not designed for developing bodies, children can face a lifetime of late effects, including cognitive delays, cardiac complications, secondary cancers and mental health burdens that follow them well into adulthood. That is not an acceptable outcome for any child.

Pediatric cancer is a journey, not just a treatment plan

Another misconception is that pediatric cancer is largely solved once a child finishes treatment. It is not.

For many families, treatment is only the beginning of a much longer journey that can include travel burdens, fragmented specialty care, financial strain, psychosocial stress and years of follow-up. Survivorship in pediatric oncology is not simply surveillance after remission. The NCI reports that 60% to more than 90% of childhood cancer survivors develop one or more chronic health conditions, and 20% to 80% experience severe or life-threatening complications during adulthood.

That is why the pediatric cancer conversation cannot stop at curing disease. Health systems need to think across the full continuum: diagnosis, treatment, survivorship, psychosocial care, care coordination and long-term quality of life. Good pediatric oncology care is not just about what happens in the infusion chair or operating room. It is also about what happens after discharge, when families are left to navigate the rest.

Healthcare leaders have a bigger role to play

Pediatric cancer remains structurally overlooked in part because it sits at the intersection of rarity and complexity. And adult cancer is not a suitable template. NCI’s TARGET program states plainly that childhood cancers can be genetically distinct from their adult counterparts, and that treatment protocols are still too often derived from adult regimens even when alternate approaches are needed.

That has practical implications. Pediatric oncology needs specialized science, tailored clinical trials, longer follow-up horizons and more durable support for emerging investigators.

Hospitals and health systems do not have to wait for another bill to act. They can strengthen referral pathways, expand survivorship services, improve access to trials, invest in pediatric research partnerships and build an interoperable data infrastructure that allows faster discovery. CCDI was created to collect, standardize and reuse pediatric cancer data for exactly this reason.

The road ahead requires more than attention

Pediatric cancer is finally getting more attention. That is welcome. But attention alone will not improve care, strengthen the research pipeline or ease the long-term burden on families.

What will? More targeted action.

That starts with more consistent funding—from government, philanthropy, nonprofits, donors and private partners willing to support early-stage pediatric research. It also requires better education for healthcare leaders and policymakers, who need to understand that pediatric cancer is biologically different from adult cancer and requires different treatment strategies, trial design and survivorship planning. And it requires smarter use of technology. AI and better data infrastructure could help accelerate research and improve care, but only if institutions are willing to share data, collaborate across systems and invest in the tools to make that possible.

The path forward is clear: stronger funding, better-informed leadership, smarter use of innovation and a healthcare system that treats pediatric cancer as the long-term clinical challenge it is.

Danielle Fragalla, MSE, is CEO of the Pediatric Cancer Research Foundation (PCRF).